UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Retina (Philadelphia, Pa.), 2017-10, Vol.37 (10), p.1847-1858

2017

Volltextzugriff (PDF)

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

CPT: pharmacometrics and systems pharmacology, 2023-09, Vol.12 (9), p.1262-1273

2023

Volltextzugriff (PDF)

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

CPT: pharmacometrics and systems pharmacology, 2022-10, Vol.11 (10), p.1358-1370

2022

Volltextzugriff (PDF)

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2852-2856

2009

Volltextzugriff (PDF)

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial

Ophthalmology (Rochester, Minn.), 2019-08, Vol.126 (8), p.1141-1154

2019

Volltextzugriff (PDF)

CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity

Cancer research (Chicago, Ill.), 2005-07, Vol.65 (13), p.5812-5817

2005

Volltextzugriff (PDF)

Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells

The FASEB journal, 2006-02, Vol.20 (2), p.337-339

2006

Volltextzugriff (PDF)

Effects of Omeprazole on Plasma Levels of Raltegravir

Clinical infectious diseases, 2009-02, Vol.48 (4), p.489-492

2009

Volltextzugriff (PDF)

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2752-2755

2009

Volltextzugriff (PDF)

Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

Clinical pharmacokinetics, 2024-04, Vol.63 (4), p.423-438

2024

Volltextzugriff (PDF)

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Antimicrobial Agents and Chemotherapy, 2009-05, Vol.53 (5), p.1747-1752

2009

Volltextzugriff (PDF)

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Clinical cancer research, 2018-05, Vol.24 (10), p.2276-2284

2018

Volltextzugriff (PDF)

Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial

Clinical pharmacokinetics, 2018-03, Vol.57 (3), p.367-377

2018

Volltextzugriff (PDF)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Frontiers in oncology, 2016-10, Vol.6, p.232-232

2016

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2011-10, Vol.17 (19), p.6304-6312

2011

Volltextzugriff (PDF)

Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients

Antimicrobial agents and chemotherapy, 2018-02, Vol.62 (2)

2018

Volltextzugriff (PDF)

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection

Journal of clinical pharmacology, 2020-11, Vol.60 (11), p.1509-1518

2020

Volltextzugriff (PDF)

A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy

The Journal of pharmacology and experimental therapeutics, 2015-11, Vol.355 (2), p.288-296

2015

Volltextzugriff (PDF)

The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation

Journal of clinical pharmacology, 2017-10, Vol.57 (10), p.1268-1278

2017

Volltextzugriff (PDF)

Distinct kinetic and mechanical properties govern selectin-leukocyte interactions

Journal of cell science, 2004-05, Vol.117 (Pt 12), p.2503-2511

2004

Volltextzugriff (PDF)

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment

International journal of clinical pharmacology and therapeutics, 2017-09, Vol.55 (9), p.746

2017

Volltextzugriff (PDF)

Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation

Journal of clinical pharmacology, 2008-02, Vol.48 (2), p.209-214

2008

Volltextzugriff (PDF)

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease

Respiratory medicine, 2011-03, Vol.105 (3), p.392-401

2011

Volltextzugriff (PDF)

Receptor–ligand binding: ‘catch’ bonds finally caught

Current biology, 2003-08, Vol.13 (15), p.R611-R613

2003

Volltextzugriff (PDF)

1 – 25 von 261

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(225)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(259)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial

CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity

Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells

Effects of Omeprazole on Plasma Levels of Raltegravir

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection

A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy

The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation

Distinct kinetic and mechanical properties govern selectin-leukocyte interactions

Pharmacokinetics of sugammadex in subjects with moderate and severe renal impairment

Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation

MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease

Receptor–ligand binding: ‘catch’ bonds finally caught

Suchergebnisse filtern